Future trends for treatment of APS.
Since the Sapporo Anti-phospholipid Antibody Conference we have learned much about the molecular and genetic biology of antiphospholipid antibody, its mechanisms of pathogenesis, detailed clinical descriptions of illness, including tests of criteria, definitions of subsets of disease, and early intimations about long-term prognosis. There has been wide application of known treatments but little testing of new ones. Rapid advances in the basic science of this illness gives us an opportunity to devise, test, and generally apply targeted biologic agents in order to prevent the short-term and long-term complications of this disease.
Lockshin
M D
MD
Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Joan and Sanford Weill College of Medicine of Cornell University, New York, NY 10021, USA. LockshinM@hss.edu
D016736:Antiphospholipid Syndrome / Q000235:genetics / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005544:Forecasting; D006801:Humans; D011247:Pregnancy